New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?

Area of Science:

• Oncology
• Genitourinary Oncology
• Translational Research

Background:

• Metastatic castration-resistant prostate cancer (mCRPC) treatment is shifting towards genomics-oriented therapies.
• DNA damage repair (DDR) defect-driven novel molecules are a growing focus for single-agent and combination strategies.

Purpose of the Study:

• To review emerging clinical research in mCRPC focusing on therapies targeting DDR pathways.
• Emphasis is placed on poly (ADP-ribose) polymerase (PARP) inhibitors, immune checkpoint (IC) inhibitors, and prostate-specific membrane antigen (PSMA)-targeting agents.
• The review prioritizes ongoing clinical studies with potential for near-future clinical translation.

Main Methods:

• A PubMed search was conducted using keywords related to prostate cancer, mCRPC, DDR pathways, ARS inhibitors, PARP inhibitors, IC inhibitors, PSMA-targeting agents, and drug combinations.
• Clinical research focusing on patients undergoing therapies with emerging molecules was selected.
• Studies currently recruiting patients were prioritized to identify treatments likely for near-future clinical care.

Main Results:

• The review focuses on emerging therapies including PARP inhibitors, IC inhibitors, and PSMA-targeting agents in mCRPC.
• Combination strategies involving androgen receptor signaling (ARS) and PARP, IC and PARP, and IC and ARS are under investigation.
• Ongoing clinical trials are exploring novel drug combinations for mCRPC treatment.

Conclusions:

• The evolving landscape of mCRPC treatment emphasizes genomics and targeted therapies.
• PARP, IC, and PSMA-inhibitor-based strategies represent promising avenues for future clinical practice.
• Focus on ongoing clinical trials ensures relevance to evolving treatment paradigms in mCRPC.